Not Losing Weight on 0.25mg Wegovy? This Is Why — and What Comes Next

The misconception worth setting aside first

A lot of people starting Wegovy expect the first pen to kickstart visible results. It's an understandable assumption, especially after reading about the trial figures. But those headline numbers (the roughly 15% average body-weight reduction that appeared in the STEP 1 trial, published in the New England Journal of Medicine) came from participants who had reached and stayed at the 2.4mg maintenance dose over 68 weeks. The 0.25mg dose was never in those calculations as a weight-loss agent. It's the opening chord, not the whole song. Once you understand that, the absence of loss at week four stops feeling like evidence you're doing something wrong.

This isn't a small technical detail buried in the prescribing information. The NHS's own semaglutide guidance is clear that the starting dose is a tolerability measure. Its purpose is to introduce GLP-1 receptor agonism gradually, reducing the chance of the nausea, bloating or discomfort that can follow a higher opening dose. Think of it less as the medicine beginning to work and more as the medicine introducing itself.

How the dose schedule is designed to build towards results

Wegovy's licensed titration pathway runs through five levels: 0.25mg, then 0.5mg, then 1.0mg, then 1.7mg, and finally 2.4mg, with around four weeks at each step. Some people may now be prescribed a higher 7.2mg maintenance dose following MHRA approval in 2026, though that pathway starts at 0.25mg too and is guided entirely by the prescriber. If you want a fuller picture of how each stage works, the dose-by-dose breakdown covers the progression in detail.

The therapeutic effect (appetite suppression, slowed gastric emptying, reduced caloric intake) builds as the dose rises. At 0.5mg, some people begin to notice their hunger shifting. By 1.0mg, the effect is more consistent for many. The clinical evidence that supports Wegovy's licence reflects the full course, not any single early step. Looking at your four-week weight reading at 0.25mg and concluding the medicine doesn't work is a bit like stepping off a flight at a connection and deciding the destination doesn't exist.

What is worth tracking during these early weeks: how you're tolerating the dose, whether side effects are manageable, and whether your prescriber has all the information they need to support your next dose step. For a broader look at what to expect from Wegovy at 0.25mg specifically, the guide to the starting dose goes into more depth.

When does actual weight loss tend to start?

There's no universal answer, because people respond differently and the titration pace depends on tolerability. That said, many people report noticeable appetite changes from around the 0.5mg step, with weight movement becoming clearer between 1.0mg and 2.4mg. The 0.5mg stage and the 1.0mg stage each have their own patterns worth reading about if you're planning ahead.

If you've moved past 0.25mg and still aren't seeing any change, the conversation shifts. Some people need more time at a given dose; others have factors worth discussing with a prescriber, such as diet composition, activity, sleep quality, or whether another condition is affecting response. NICE guidance on semaglutide suggests reviewing continuation if there's been less than 5% weight loss after six months at the maintenance dose, but that's a maintenance-dose assessment, not something applied to the starter step.

It's also worth noting that weight isn't the only thing changing in these early weeks. Improvements in blood pressure, blood glucose, and even energy levels can precede visible scale changes. That doesn't mean you should ignore a persistent lack of response, it means the picture is sometimes bigger than the number on the display.

What to do if you're concerned about your progress

The most useful thing at this stage is an honest conversation with your prescriber, and if you're still in the early stages it may help to understand what the starting dose of Wegovy is actually designed to do before that conversation. They can review whether your dose titration is on track, check that nothing in your history is affecting the medicine's action, and support you through the adjustment period. Aftercare isn't a nice-to-have with a prescription medicine, it's where the clinical value actually lives.

If you started through a private service and feel unsupported between doses, that's worth addressing directly. At nume, prescribers are available seven days a week for exactly these moments, and every repeat order is clinically reviewed before it's processed, not as a formality, but because dose decisions matter. You can read more about how Wegovy is used for weight management across the full treatment course on the Wegovy overview page.

If you're at the early stages and thinking about whether this is the right route for you, or if you'd like a prescriber to look at your specific picture, check your eligibility with our clinical team, the consultation is free, and there's no obligation to proceed.